JP2013527224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527224A5 JP2013527224A5 JP2013513002A JP2013513002A JP2013527224A5 JP 2013527224 A5 JP2013527224 A5 JP 2013527224A5 JP 2013513002 A JP2013513002 A JP 2013513002A JP 2013513002 A JP2013513002 A JP 2013513002A JP 2013527224 A5 JP2013527224 A5 JP 2013527224A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- drug
- level
- transfer agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000036765 blood level Effects 0.000 claims 7
- 230000036470 plasma concentration Effects 0.000 claims 7
- 210000002966 serum Anatomy 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 210000001198 duodenum Anatomy 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 210000001630 jejunum Anatomy 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940126701 oral medication Drugs 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004267 taurolidine Drugs 0.000 claims 2
- 229950007343 taurultam Drugs 0.000 claims 2
- WUHXNMJSNJXJEZ-UHFFFAOYSA-N 2-(hydroxymethylamino)ethanesulfonic acid Chemical compound OCNCCS(O)(=O)=O WUHXNMJSNJXJEZ-UHFFFAOYSA-N 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 201000011603 cardia cancer Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000025036 lymphosarcoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35018310P | 2010-06-01 | 2010-06-01 | |
| US61/350,183 | 2010-06-01 | ||
| US37031510P | 2010-08-03 | 2010-08-03 | |
| US61/370,315 | 2010-08-03 | ||
| PCT/IB2011/001539 WO2011151722A2 (en) | 2010-06-01 | 2011-06-01 | Methods and compositions for oral pharmaceutical therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016037487A Division JP2016155826A (ja) | 2010-06-01 | 2016-02-29 | 経口薬物療法のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527224A JP2013527224A (ja) | 2013-06-27 |
| JP2013527224A5 true JP2013527224A5 (enExample) | 2014-07-17 |
| JP5926243B2 JP5926243B2 (ja) | 2016-05-25 |
Family
ID=45067142
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513002A Active JP5926243B2 (ja) | 2010-06-01 | 2011-06-01 | 経口薬物療法のための方法および組成物 |
| JP2016037487A Withdrawn JP2016155826A (ja) | 2010-06-01 | 2016-02-29 | 経口薬物療法のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016037487A Withdrawn JP2016155826A (ja) | 2010-06-01 | 2016-02-29 | 経口薬物療法のための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9028866B2 (enExample) |
| EP (1) | EP2575783B1 (enExample) |
| JP (2) | JP5926243B2 (enExample) |
| CN (1) | CN103118669B (enExample) |
| AU (1) | AU2011262308B2 (enExample) |
| BR (1) | BR112012030641B8 (enExample) |
| CA (1) | CA2801309C (enExample) |
| ES (1) | ES2614878T3 (enExample) |
| WO (1) | WO2011151722A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301374B2 (en) * | 2012-05-15 | 2016-03-29 | Koninklijke Philips N.V. | Control of lighting devices |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| CA3010981C (en) * | 2016-01-11 | 2024-09-17 | Cormedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
| US20190381058A1 (en) * | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Methods and compositions for treating neuroblastoma in a juvenile mammalian body |
| US11541061B2 (en) | 2016-01-11 | 2023-01-03 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
| PL3709979T3 (pl) | 2017-11-17 | 2025-03-24 | Evonik Operations Gmbh | Sposób wytwarzania powlekanej kapsułki twardej |
| CN113347976A (zh) * | 2018-08-28 | 2021-09-03 | 科医公司 | 用牛磺罗定水解产物进行的神经母细胞瘤治疗 |
| WO2020047530A1 (en) * | 2018-08-31 | 2020-03-05 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| WO2020234833A1 (en) | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Method for treating, preventing, inhibiting or reducing cytokine release |
| US20220323452A1 (en) * | 2019-05-22 | 2022-10-13 | Geistlich Pharma Ag | Methods and compositions for inhibiting gapdh |
| CN111671758A (zh) * | 2020-07-06 | 2020-09-18 | 长春迈灵生物工程有限公司 | 牛磺罗定在制备抗hiv病毒药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
| IE66933B1 (en) * | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| US5972933A (en) * | 1998-01-08 | 1999-10-26 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of treating microbial infections |
| US6555534B1 (en) * | 1998-09-11 | 2003-04-29 | Medpointe Healthcare Inc. | Method and compositions for the control or eradication of Helicobacter pylori |
| US6251896B1 (en) * | 1999-03-24 | 2001-06-26 | Carter-Wallace, Inc. | Compositions and methods for the management of Crohn's disease |
| WO2001013957A2 (en) * | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| EP1246617B1 (en) * | 1999-12-06 | 2006-09-13 | Rhode Island Hospital | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer |
| US20020004502A1 (en) * | 2000-01-05 | 2002-01-10 | Redmond H. Paul | Treatment of inflammatory bowel disease |
| US20040170617A1 (en) * | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AU779362B2 (en) * | 2000-10-27 | 2005-01-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| JP5502254B2 (ja) * | 2001-01-31 | 2014-05-28 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 少なくとも２種類の異なる被覆ペレット形から成る多粒子剤形 |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| EP2260845A3 (fr) | 2002-06-21 | 2012-08-22 | L'Oréal | Utilisation de polyphénol pour le traitement de l'alopécie |
| US20060198886A1 (en) * | 2005-03-01 | 2006-09-07 | Jenkins Richard B | Medicament having coated methenamine combined with acidifier |
| EA015781B1 (ru) * | 2005-10-21 | 2011-12-30 | Панацея Биотек Лимитед | Композиции для лечения рака |
| ATE414518T1 (de) * | 2006-07-25 | 2008-12-15 | Claus Herdeis | Herstellung von antimikrobiellen formulierungen unter verwendung von 7-oxa-2-thia 1,5- diazabicycloä3.3.1ünonan-2,2-dion |
-
2011
- 2011-06-01 ES ES11758551.3T patent/ES2614878T3/es active Active
- 2011-06-01 EP EP11758551.3A patent/EP2575783B1/en active Active
- 2011-06-01 JP JP2013513002A patent/JP5926243B2/ja active Active
- 2011-06-01 AU AU2011262308A patent/AU2011262308B2/en active Active
- 2011-06-01 WO PCT/IB2011/001539 patent/WO2011151722A2/en not_active Ceased
- 2011-06-01 US US13/701,372 patent/US9028866B2/en active Active
- 2011-06-01 CN CN201180036488.8A patent/CN103118669B/zh active Active
- 2011-06-01 BR BR112012030641A patent/BR112012030641B8/pt not_active IP Right Cessation
- 2011-06-01 CA CA2801309A patent/CA2801309C/en active Active
-
2016
- 2016-02-29 JP JP2016037487A patent/JP2016155826A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102490334B1 (ko) | 암 치료용 아젤니디핀 약학 조성물의 새로운 적응증 | |
| CN102612365B (zh) | 用于强化dna损伤剂的检查点激酶1抑制剂 | |
| CN103118669B (zh) | 口服药物治疗方法和组合物 | |
| Singh et al. | Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma | |
| AU2016297555B2 (en) | Methods for treating cancer using apilimod | |
| US20160279141A1 (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
| JP2022533578A5 (enExample) | ||
| KR20010024032A (ko) | 시너지 효과를 위한 오피오이드 진통제와싸이클로옥시게나아제-2 저해제의 진통제 조합 | |
| TW202214243A (zh) | 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用 | |
| JP2019534330A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| TW202214242A (zh) | 西奧羅尼或其衍生物在製備用於預防和/或治療非霍奇金淋巴瘤的藥物之用途 | |
| JP2024152860A5 (enExample) | ||
| JP2014512355A5 (enExample) | ||
| Koustas et al. | Role of autophagy in cholangiocarcinoma: an autophagy-based treatment strategy | |
| JP2020521786A5 (enExample) | ||
| Hao et al. | Mechanism and application of HDAC inhibitors in the treatment of hepatocellular carcinoma | |
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| RU2016116915A (ru) | Комбинация | |
| JP2024515215A5 (enExample) | ||
| JP2021501143A5 (enExample) | ||
| Saha et al. | 12 drug repurposing of selective COX-2 inhibitors in the pursuit of new therapeutic avenues | |
| CN106038566B (zh) | 一种用于胃癌治疗的药物组合物及其应用 | |
| US20180110757A1 (en) | Methods of treating pruritis and pain | |
| CN107137403B (zh) | 一种pi3k/mtor抑制剂在制备治疗胰腺癌的药物中的用途 |